Human Psychopharmacology: Clinical and Experimental最新文献

{"title":"Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA)","authors":"Levi J. M. Schuurman,&nbsp;Sjacko Sobczak,&nbsp;Julie E. M. Schulkens,&nbsp;Benno P. F. Balter,&nbsp;Sebastiaan P. J. van Alphen","doi":"10.1002/hup.70009","DOIUrl":"https://doi.org/10.1002/hup.70009","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Patient-reported side-effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side-effect questionnaires are less suitable for older adults because they often lack age-specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Procedures</h3>\u0000 \u0000 <p>Psychometric properties of the SCOPA were assessed in a Dutch patient population (<i>n</i> = 205, age 18–86 years) and a general population (<i>n</i> = 281, age 18–87 years). Reliability of the subscales was measured through average inter-item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Average inter-item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two-factor solution, labelled as complaints in somatic and cognitive domains.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side-effect burden of treatment with psychotropic medication across the adult-aged-spectrum. However, more research is needed to cross-validate these results in the field's pursuit of increased patient safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zopiclone as a Potent Positive Control for Assessing the Residual Effects of Hypnotic Drugs on Next Day Driving Performance: A Systematic Review","authors":"Sonali Karhana,&nbsp;Samra Hussain,&nbsp;Mohammad Mateen Zehgeer,&nbsp;Mohd. Ashif Khan","doi":"10.1002/hup.70007","DOIUrl":"https://doi.org/10.1002/hup.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This systematic review aimed to evaluate the efficacy of zopiclone as a potent positive control for the assessment of residual effects of hypnotic drugs on the next day driving performance in clinical trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>Online databases and websites were used to conduct a literature search to identify relevant clinical trials encompassing the use of zopiclone as a positive control and the trials examining the residual effects of zopiclone on the next day driving performance. A total of 22 articles were identified and as per the inclusion criteria, 16 were selected for final data retrieval.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The average difference in Standard Deviation of Lateral Position (SDLP) between zopiclone and a placebo ranged from 1.6 to 4.74 cm. On average, this difference was about 2.51 cm, indicating significant impairment in driving ability the day after taking zopiclone. Therefore, current studies demonstrate zopiclone administration impairs driving performance, as indicated by increased standard deviation of lateral position (SDLP) values. Additionally, the reported adverse events included somnolence, dyspepsia, fatigue, headache, dizziness, gastrointestinal disorders, and upper respiratory tract problems.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Zopiclone can serve as a reliable positive control in future clinical trials assessing the residual effects of hypnotic drugs on next-day driving performance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 4","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clozapine Once-Versus Multiple-Daily Dosing Regimen: A Single-Center, Retrospective, Cross-Sectional Study","authors":"Jing Ding,&nbsp;Suo Zhang,&nbsp;Huan Xing,&nbsp;Luyao Li","doi":"10.1002/hup.70006","DOIUrl":"https://doi.org/10.1002/hup.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Due to its short plasma half-life, clozapine is typically prescribed in a divided dosing regimen. Although once-daily dosing has proven effective in countries such as Japan, South Korea, Canada, and the United States, its adoption in real-world clinical practice in China remains unclear. This study aimed to compare patient characteristics, psychiatric symptoms, side effects, and plasma clozapine concentrations between once-daily and divided dosing regimens, and to determine the dosage required to achieve plasma levels of 350–600 ng/mL in the Chinese population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a single-center, retrospective, cross-sectional study at Xi'an Mental Health Center, China, collecting data on clozapine-treated patients from March 2019 to March 2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients (80% of 198) in the Chinese cohort followed a divided-dose regimen in clinical practice. In the once-daily dosing group, the average plasma clozapine concentration was 158.75 ng/mL, with only 8% of patients reaching the therapeutic window. Conversely, patients on a divided dosing regimen had significantly higher plasma concentrations, averaging 373.34 ng/mL, with 28% within the therapeutic window. The psychiatric symptom remission rate did not differ significantly between the once-daily and divided-dosing groups (50.05% vs. 52.72%, <i>p</i> = 0.718); however, the divided-dosing group experienced a greater variety of adverse effects. Receiver operating characteristic analysis indicated that patients on multiple daily doses require a total daily clozapine dose of 150–250 mg to achieve the target plasma concentration, corresponding to a clozapine concentration-to-dose ratio of 1.4–2.4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Chinese clinicians generally adhere to a divided dosing schedule for clozapine when the daily dose exceeds 50 mg. Further prospective longitudinal studies are warranted to evaluate whether once-daily dosing regimens can improve clinical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Placebo-Controlled Clinical Trial Exploring the Short-Term Cognitive and Cerebrovascular Effects of Consuming Peppermint Tea: A Mediation Study","authors":"Luka Netzler,&nbsp;Brian Lovell","doi":"10.1002/hup.70005","DOIUrl":"https://doi.org/10.1002/hup.70005","url":null,"abstract":"<p>The cognitive-enhancing effects of peppermint have been widely reported. Vasodilation, causing an increase in cerebral blood flow (CBF) in the prefrontal cortex, has been implicated as a possible mediator. We tested this here. A total of <i>N</i> = 25 individuals, all aged over 18 years, were recruited via convenience sampling. A randomized, single blind placebo-controlled, independent groups design was used to assess whether groups (peppermint vs. placebo control) could be differentiated with respect to change in cognition, assessed via a computerized battery, and change in cerebral blood flow, assessed with Near-Infrared-Spectroscopy (NIRS), from pre-post intervention. Groups disparities in both cognitive and cerebrovascular change scores (from pre-post intervention) emerged. Improvements in cognitive performance were better in the peppermint group. Increases in hemodynamic activity, indexed by Oxygenated (Oxy-Hb) and Total hemoglobin (Total-Hb), were also greater in the peppermint group. Cerebrovascular changes from pre-to post-intervention were unrelated to cognitive changes over the same period, ruling out mediation effects. In conclusion, 200 mL of peppermint, consumed as tea, effectively boosted cognition and cerebral blood flow in otherwise healthy adults. Increased cerebral blood flow, however, did not mediate the cognitive-enhancing effects of peppermint. Future research incorporating larger samples and exploring other neurophysiological mediators is encouraged.</p>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol Consumption During the COVID-19 Pandemic: A Critical Review","authors":"A. Merlo,&nbsp;P.A. Hendriksen,&nbsp;N.R. Severeijns,&nbsp;J. Garssen,&nbsp;G. Bruce,&nbsp;J.C. Verster","doi":"10.1002/hup.70004","DOIUrl":"https://doi.org/10.1002/hup.70004","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The purpose of this systematic review was to summarize the impact of the 2019 coronavirus disease (COVID-19) pandemic on individuals' alcohol consumption.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed was searched to identify relevant studies. Articles were included if they provided information on overall (changes in) alcohol consumption, and factors that may influence alcohol consumption including demographics, socioeconomic status, educational background, living situation, and health status. Following screening, 100 articles were identified and included in this review.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall findings show no change (51%) or a reduction (23%) in alcohol consumption during the COVID-19 pandemic. However, across countries, on average 1 in 4 individuals reported an increase in alcohol consumption (26%), in particular during the COVID-19 lockdown periods. Most common correlates of increased alcohol consumption were being female, having a child at home, higher educational level, and poorer mental health (including higher scores for stress, anxiety and depression).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although overall alcohol consumption was reduced during the COVID-19 pandemic, a considerable subpopulation of drinkers increased their alcohol consumption.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 2","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2-Year Italian Follow-Up Study","authors":"Lorenzo Pelizza,&nbsp;Alessandro Di Lisi,&nbsp;Emanuela Leuci,&nbsp;Emanuela Quattrone,&nbsp;Derna Palmisano,&nbsp;Simona Pupo,&nbsp;Pietro Pellegrini,&nbsp;Marco Menchetti","doi":"10.1002/hup.70003","DOIUrl":"https://doi.org/10.1002/hup.70003","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Despite various models examining baseline factors, predicting outcomes in individuals at clinical high risk for psychosis (CHR-P) remains challenging. Specifically, neglecting factors like ongoing antipsychotic (AP) medications introduce bias and reduce method precision. The main aim of this research was to determine if the presence of AP prescription at baseline identifies a CHR-P subgroup with worse prognostic outcomes over a 2-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A group of 180 FEP individuals (92 CHR-P/AP+, 88 CHR-P/AP−) were evaluated at baseline and after 24 months using the PANSS and GAF scales. Individuals with baseline AP prescription were included in the CHR-P/AP+ subgroup; those not taking APs were grouped as CHR-P/AP−. Univariate Cox regression analysis and mixed-design ANOVA were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After 2 years, CHR-P/AP+ had a higher rate of new hospitalization but lower rate of service disengagement. No significant inter-group difference in psychosis transition rate was found. A “time-×-group” interaction effect on longitudinal improvement in PANSS total score was observed in CHR-P/AP+ subjects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>It is advisable to conduct a more extensive outcome evaluation beyond the psychometric criteria for CHR-P and the mere consideration of psychosis transition. Such an approach would facilitate the identification of specific CHR-P subgroups with divergent prognoses and different AP response.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 2","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Administration of 10 mg Methylphenidate on Cognitive Performance and Visual Scanning in Healthy Adults: Randomised, Double-Blind, Placebo-Controlled Study","authors":"Blair Aitken,&nbsp;Luke A. Downey,&nbsp;Serah Rose,&nbsp;Brooke Manning,&nbsp;Thomas R. Arkell,&nbsp;Brook Shiferaw,&nbsp;Amie C. Hayley","doi":"10.1002/hup.70002","DOIUrl":"https://doi.org/10.1002/hup.70002","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To examine the effect of a low dose (10 mg) of methylphenidate on cognitive performance, visuospatial working memory (VSWM) and gaze behaviour capabilities in healthy adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This randomised, double-blind, placebo-controlled and crossover study examined the effects of 10 mg methylphenidate on cognitive performance, VSWM and gaze behaviour. Fixation duration and rate, gaze transition entropy, and stationary gaze entropy were used to quantify visual scanning efficiency in 25 healthy adults (36% female, mean ± SD age = 33.5 ± 7.8 years, BMI = 24.1 ± 2.9 kg/m²). Attention, memory, and reaction time were assessed using the E-CogPro test battery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Methylphenidate significantly enhanced performance in numeric working memory tasks, reflected by reduced errors and increased accuracy relative to placebo. No significant changes were observed in other cognitive or visual scanning metrics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A low dose of methylphenidate improves limited domains of psychomotor speed and accuracy but does not affect visual scanning efficiency. This suggests limited usefulness as a general pro-cognitive aid and raises the possibility of a lower threshold of effect for measurable psychostimulant-induced changes to visual scanning behaviour. Further research is needed to explore these potential dose-response relationships and effects across diverse populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ACTRN12620000499987</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 2","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143380111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of COVID-19 Lockdowns on Alcohol Consumption, Hangovers and Smoking Among Young Adults (n = 140) in Germany: An On-Line Study","authors":"Agnese Merlo,&nbsp;Anna H. Koyun,&nbsp;Pauline A. Hendriksen,&nbsp;Johan Garssen,&nbsp;Gillian Bruce,&nbsp;Ann-Kathrin Stock,&nbsp;Joris C. Verster","doi":"10.1002/hup.70000","DOIUrl":"10.1002/hup.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study investigated the impact of 2019 coronavirus disease (COVID-19) lockdowns on alcohol consumption and smoking behavior among young adults from Germany.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An online survey was completed by <i>N</i> = 317 young adults living in Germany. Of these, 140 (44.2%) consumed alcohol and were included in the analysis. They reported on alcohol consumption, hangover frequency and severity, and smoking behavior across four time periods: (1) “BP” (the period before the COVID-19 pandemic), (2) “L1” (the first lockdown; March–May, 2020), (3), NL1 (the no lock-down period; summer 2020), and (4) L2 (the second lockdown, November 2020 to May 2021).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During L1, a significant decrease was observed in weekly alcohol intake, the number of drinking days, and the number of days where more than eight alcoholic drinks were consumed. Whereas hangover frequency was significantly increased during L1, hangover severity was significantly reduced. During NL1, drinking behaviors returned to BP levels. During L2, the decrease in alcohol consumption was much smaller, and not significantly different from BP. However, compared to BP, during L2 hangover frequency was significantly increased and hangover severity was significantly reduced. With regards to smoking, no significant differences compared to BP were found.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>During the COVID-19 lockdown periods in Germany, a significant decrease in alcohol consumption was observed among this group of young adults. Whereas hangover frequency was significantly increased during the lockdown periods, hangover severity was significantly reduced.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 2","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Naturalistic Examination of the Acute Effects of High-Potency Cannabis on Emotion Regulation Among Young Adults: A Pilot Study","authors":"Jessica M. Cavalli,&nbsp;Carrie Cuttler,&nbsp;Anita Cservenka","doi":"10.1002/hup.2915","DOIUrl":"10.1002/hup.2915","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Despite the popular public perception that cannabis use may be beneficial for relieving mental health symptoms, the empirical evidence remains equivocal. Various legal hurdles limit the ability to research whether acute high-potency cannabis use affects mental health-related processes. Therefore, the current study used a novel methodology to examine the acute effects of high-potency cannabis flower on emotion regulation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using a remote, within-subjects study design, 12 young adult (ages 21–30) cannabis users (who used cannabis at least 1 day/week on average across the past year) completed measures of emotion regulation while sober and acutely intoxicated in a counterbalanced manner. Participants completed the Emotional Go/No-Go Task to measure implicit emotion regulation and a cognitive reappraisal task to assess explicit emotion regulation. For the intoxication condition, participants were observed smoking cannabis flower in their homes via videoconferencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants reported a more positive mood and decreases in anxiety while intoxicated. There was no evidence that acute high-potency cannabis affected participants' implicit or explicit emotion regulation task performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Future research with larger samples might consider adopting this novel remote study design to assess the acute effects of high-potency cannabis use on different measures of emotion regulation and other health outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nick Drake: A Troubled Mind, a Troublesome ‘Cure’","authors":"David S. Baldwin","doi":"10.1002/hup.2916","DOIUrl":"10.1002/hup.2916","url":null,"abstract":"&lt;p&gt;The British Association for Psychopharmacology (BAP) concluded its Fiftieth Anniversary Summer Meeting in July 2024 with a plenary symposium in which BAP stalwarts glanced back and looked forward, to identify achievements in psychopharmacology since 1999 and consider likely developments in neuroscience before 2049. There was much to ponder, whilst travelling home from the University of Birmingham: and my dream-like musings continued that same evening, when the BBC Radio 3 Promenade (‘Prom’) concert broadcast was devoted solely to ‘An Orchestral Celebration’ of the music of Nick Drake, who died when aged only twenty-six, almost fifty years before, in November 1974.&lt;/p&gt;&lt;p&gt;Born in Rangoon, Burma (now Yangon, Myanmar), to expatriate Britons—his father worked as a Civil Engineer, his mother came from a senior Indian Civil Service family—Nicholas Rodney Drake moved with his family to the UK as a toddler, went to a preparatory boarding school, then boarded at Marlborough College, before somewhat unexpectedly scraping into Fitzwilliam College Cambridge in 1967, to read English Literature. But he left Cambridge two years later, nine months before graduation, against the advice of his tutors and family, to further his musical career: his first album, the wistful and pastoral &lt;i&gt;Five Leaves Left&lt;/i&gt; had been released a few months earlier. A strike-delayed second album, &lt;i&gt;Bryter Later&lt;/i&gt;, sometimes considered to be ensemble-heavy, appeared in March 1971. Both were critically acclaimed by music journalists and other musicians, but neither gained much traction with the buying public. His third album, the desolate and intermittently agitated &lt;i&gt;Pink Moon&lt;/i&gt;, was released in February 1972, but probably sold less than its predecessors.&lt;/p&gt;&lt;p&gt;Characteristically reticent and often seeming aloof, he became steadily more isolated and withdrawn, possibly linked to or worsened by regular smoking of cannabis, which he started before University. He declared himself increasingly reluctant to play the live concerts which could probably have led to wider recognition and greater sales. Although he was an astonishingly adept, technically innovative guitarist and widely respected lyricist, it was more challenging for him to synchronise playing with singing. He sought company but was uncommunicative whilst in it. He neglected himself, seemed erratic and unpredictable, and sometimes had observable difficulty in sequencing tasks, such as making tea. Increasing parental concern prompted admission to the local inpatient psychiatric unit, where after a few weeks the thoughtful, compassionate consultant psychiatrist suggested their 23-year old son might suffer from simple-type schizophrenia.&lt;/p&gt;&lt;p&gt;Psychiatric diagnoses can be unreliable, and treatment plans are often contested. Drake himself stated that taking medication was ‘against my principles’. The well-meaning social worker attached to the local unit indicated that psychotropic medication was not as beneficial as psychoth","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}